Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Published online March 2, 2007
Diabetes Care 30:1187-1192, 2007
DOI: 10.2337/dc06-1915
© 2007 by the American Diabetes Association
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dc06-1915v1
30/5/1187    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Preumont, V.
Right arrow Articles by Buysschaert, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Preumont, V.
Right arrow Articles by Buysschaert, M.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Pathophysiology/Complications
Original Article

Glucose Homeostasis and Genotype-Phenotype Interplay in Cystic Fibrosis Patients With CFTR Gene {Delta}F508 Mutation

Vanessa Preumont, MD1, Michel P. Hermans, MD, PHD1, Patrick Lebecque, MD, PHD2 and Martin Buysschaert, MD, PHD1

1 Department of Endocrinology and Nutrition, Université Catholique de Louvain, Cliniques Universitaires St-Luc, Brussels, Belgium
2 Cystic Fibrosis Unit, Université Catholique de Louvain, Cliniques Universitaires St-Luc, Brussels, Belgium

Address correspondence and reprint requests to Prof. M. Buysschaert, Cliniques Universitaires St-Luc, Service d'Endocrinologie et Nutrition, Avenue Hippocrate 54, UCL 5474, B-1200 Brussels, Belgium. E-mail: buysschaert{at}diab.ucl.ac.be

OBJECTIVE—We sought to determine the clinical phenotype of adolescent/adult patients with cystic fibrosis, according to heterozygosity or homozygosity for cystic fibrosis transmembrane regulator (CFTR) {Delta}F508 mutation, and to analyze their characteristics according to glucose tolerance status.

RESEARCH DESIGN AND METHODS—A total of 76 cystic fibrosis patients with CFTR {Delta}F508 mutation (33 heterozygous and 43 homozygous) stratified according to normal glucose tolerance (NGT) (n = 51) or abnormal glucose homeostasis (AGH) (impaired fasting glucose, impaired glucose tolerance, or diabetes; n = 25) had their homeostasis model assessment (HOMA) of ß-cell function and of insulin sensitivity and hyperbolic product (ß-cell function x insulin sensitivity [B x S]) measured. Pancreatic exocrine insufficiency was inferred from pancreatine requirements. Clinical effects of insulin therapy on weight and lung function were recorded.

RESULTS—AGH was observed in 24 and 40% of heterozygous and homozygous subjects, respectively. AGH patients were older than NGT patients (mean ± SD age 29 ± 10 vs. 23 ± 8 years, P = 0.006), and their ß-cell function was lower (93 ± 49 vs. 125 ± 51%, P = 0.011). Insulin sensitivity values were comparable in NGT and AGH patients. A lower B x S product was observed in AGH, although it was nonsignificant when adjusted for error propagation. Pancreatic insufficiency was observed in 52 and 100% of heterozygous and homozygous patients (P = 0.001).

CONCLUSIONS—Pre-diabetes and diabetes represent frequent comorbidities in CFTR {Delta}F508 mutation in the homozygous or heterozygous states. Impairment of insulin secretion, as shown by HOMA, is an important determinant when compared with the magnitude of compensation from insulin sensitivity. Given the high prevalence of abnormal glucose tolerance, screening for (pre-)diabetes is mandatory. Insulin supplementation in diabetic subjects with CFTR {Delta}F508 mutation seems a rational therapy for consideration, although this does not preclude that therapy directed toward insulin resistance could also interact.

Abbreviations: AGH, abnormal glucose homeostasis • B x S, ß-cell function x insulin sensitivity • FEV1, forced expiratory volume over 1 s • FVC, forced vital capacity • HOMA, homeostasis model assessment • HOMA-B, HOMA of ß-cell function • HOMA-S, HOMA of insulin sensitivity • IFG, impaired fasting glucose • IGT, impaired glucose tolerance • NGT, normal glucose tolerance


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Diabetes CareHome page
A. I. Adler, B. S.F. Shine, P. Chamnan, C. S. Haworth, and D. Bilton
Genetic Determinants and Epidemiology of Cystic Fibrosis-Related Diabetes: Results from a British cohort of children and adults
Diabetes Care, September 1, 2008; 31(9): 1789 - 1794.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2007 by the American Diabetes Association.